New drug delivery system for treating lung diseases
Bispecific immunotherapeutic delivery system for lung diseases
This study is testing a new way to deliver medicine directly to the lungs to help people with lung diseases like Acute Respiratory Distress Syndrome (ARDS), aiming to make treatments work better while causing fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Proteogenomics Research Instit/sys/ Med NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11103179 on NIH RePORTER |
What this research studies
This research focuses on developing a novel drug delivery system designed to improve the treatment of lung diseases, particularly Acute Respiratory Distress Syndrome (ARDS). The approach involves creating a bispecific immunotherapeutic that can effectively target and penetrate lung tissue, overcoming barriers that typically hinder drug delivery. By utilizing a method that enhances the transport of therapeutics directly into the lungs, the goal is to minimize exposure to other tissues and reduce potential side effects. Patients may benefit from a more effective treatment with fewer complications and lower costs.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Acute Respiratory Distress Syndrome or other severe lung conditions.
Not a fit: Patients with mild respiratory issues or those not diagnosed with acute lung diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients suffering from lung diseases.
How similar studies have performed: While the approach of targeted drug delivery is being explored in various contexts, this specific method for lung diseases is relatively novel and has not been extensively tested.
Where this research is happening
La Jolla, United States
- Proteogenomics Research Instit/sys/ Med — La Jolla, United States (Active)
Researchers
- Principal investigator: Schnitzer, Jan Eugeniusz — Proteogenomics Research Instit/sys/ Med
- Study coordinator: Schnitzer, Jan Eugeniusz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.